GeneDx Holdings Corp. $WGS Shares Bought by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd grew its position in shares of GeneDx Holdings Corp. (NASDAQ:WGS) by 132.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 14,839 shares of the company’s stock after purchasing an additional 8,459 shares during the period. Y Intercept Hong Kong Ltd owned 0.05% of GeneDx worth $1,599,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. AlphaQuest LLC increased its stake in shares of GeneDx by 351.5% during the 2nd quarter. AlphaQuest LLC now owns 763 shares of the company’s stock valued at $70,000 after acquiring an additional 594 shares during the last quarter. Tower Research Capital LLC TRC increased its position in GeneDx by 479.0% during the second quarter. Tower Research Capital LLC TRC now owns 1,818 shares of the company’s stock worth $168,000 after purchasing an additional 1,504 shares during the last quarter. Ameritas Investment Partners Inc. raised its stake in GeneDx by 61.0% during the second quarter. Ameritas Investment Partners Inc. now owns 1,917 shares of the company’s stock worth $177,000 after purchasing an additional 726 shares during the period. State of Alaska Department of Revenue acquired a new position in shares of GeneDx in the 3rd quarter valued at $187,000. Finally, Campbell & CO Investment Adviser LLC purchased a new stake in shares of GeneDx during the 2nd quarter valued at $204,000. Institutional investors and hedge funds own 61.72% of the company’s stock.

Insider Buying and Selling at GeneDx

In related news, Director Joshua Ruch sold 38,000 shares of the stock in a transaction that occurred on Monday, November 24th. The stock was sold at an average price of $160.37, for a total value of $6,094,060.00. Following the completion of the transaction, the director directly owned 11,941 shares of the company’s stock, valued at $1,914,978.17. This represents a 76.09% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Katherine Stueland sold 10,857 shares of the stock in a transaction that occurred on Tuesday, December 16th. The shares were sold at an average price of $143.89, for a total transaction of $1,562,213.73. Following the completion of the transaction, the chief executive officer owned 14,237 shares of the company’s stock, valued at $2,048,561.93. This trade represents a 43.27% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 57,617 shares of company stock worth $8,992,161. 29.60% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the company. Wells Fargo & Company set a $155.00 price objective on GeneDx and gave the stock an “equal weight” rating in a report on Monday, December 15th. BTIG Research boosted their price objective on shares of GeneDx from $165.00 to $200.00 and gave the stock a “buy” rating in a research note on Friday, December 12th. Guggenheim reissued a “buy” rating and issued a $170.00 price objective (up previously from $115.00) on shares of GeneDx in a research report on Wednesday, October 29th. Weiss Ratings restated a “sell (d)” rating on shares of GeneDx in a report on Wednesday, January 21st. Finally, Canaccord Genuity Group raised their price objective on GeneDx from $160.00 to $170.00 and gave the company a “buy” rating in a research report on Monday, December 22nd. Six research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $138.13.

GeneDx Stock Performance

WGS stock opened at $96.26 on Friday. The firm has a market cap of $2.78 billion, a P/E ratio of 1,069.56 and a beta of 2.01. The stock’s 50 day simple moving average is $133.71 and its 200 day simple moving average is $124.27. The company has a current ratio of 2.71, a quick ratio of 2.59 and a debt-to-equity ratio of 0.18. GeneDx Holdings Corp. has a 12-month low of $55.17 and a 12-month high of $170.87.

GeneDx (NASDAQ:WGS) last issued its earnings results on Tuesday, October 28th. The company reported $0.49 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.28 by $0.21. GeneDx had a net margin of 0.52% and a return on equity of 20.22%. The firm had revenue of $116.74 million for the quarter, compared to analysts’ expectations of $104.33 million. As a group, equities research analysts predict that GeneDx Holdings Corp. will post 0.97 EPS for the current year.

About GeneDx

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.